CCR5 as a Potential Target in Cancer Therapy: Inhibition or Stimulation?

被引：15

作者：

Gonzalez-Martin, Alicia ^{[2
]}

Mira, Emilia ^{[1
]}

Manes, Santos ^{[1
]}

机构：

[1] CSIC, CNB, Dept Immunol & Oncol, E-28049 Madrid, Spain

[2] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA

来源：

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY | 2012年 / 12卷 / 09期

关键词：

CCR5; Chemokines; Crosspriming; Immune Response; Immunotherapy; Inflammation; Maraviroc; Tumor microenvironment; CHEMOKINE RECEPTOR CCR5; IMMUNODEFICIENCY-VIRUS TYPE-1; CD8(+) T-CELLS; INFECTION IN-VITRO; TUMOR-DERIVED CCL5; BREAST-CANCER; DENDRITIC CELLS; PROGNOSTIC-FACTOR; MONOCLONAL-ANTIBODY; CERVICAL-CANCER;

D O I：

10.2174/187152012803529637

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Extensive evidence implicates CCR5 and its ligands in the biology of tumors, although there is considerable controversy regarding the role of this chemokine receptor in cancer progression. The discrepancies between the pro- and anti-tumor effects of CCR5 might derive from its expression by cell types with opposing functions in tumor progression and the context in which tumors originate. We propose that CCR5 is necessary for optimal activation of the adaptive immune response to tumors, and for the success of certain immunotherapeutic strategies. Since efficient activation of T cell responses has broad implications in the success of some chemo-and radiotherapy protocols, activation of CCR5, rather than its inhibition, might provide new therapeutic opportunities for cancer treatment.

引用

页码：1045 / 1057

页数：13

共 50 条

[21] CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer
Pervaiz, Asim
Zepp, Michael
Mahmood, Saqib
Ali, Doaa Mohamed
Berger, Martin R.
Adwan, Hassan
CELLULAR ONCOLOGY, 2019, 42 (01) : 93 - 106
[22] CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer
Asim Pervaiz
Michael Zepp
Saqib Mahmood
Doaa Mohamed Ali
Martin R. Berger
Hassan Adwan
Cellular Oncology, 2019, 42 : 93 - 106
[23] Therapeutic potential of blocking CCR5 by maraviroc in breast cancer bone metastasis
Pervaiz, Asim
Zepp, Michael
Ali, Doaa M.
Berger, Martin R.
Adwan, Hassan
CANCER RESEARCH, 2016, 76
[24] The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer
Weitzenfeld, Polina
Ben-Baruch, Adit
CANCER LETTERS, 2014, 352 (01) : 36 - 53
[25] The role of the gene CCR5 polymorphisms CCR5Δ32 e CCR5 59029 in ocular toxoplasmosis.
Faria Junior, G. M.
Ayo, C. M.
Murata, F. H. A.
Frederico, F. B.
Lopes, A. G.
Oliveira, A. P.
de Mattos, L. C.
de Mattos, C. C. B.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 73 : 110 - 110
[26] The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer
Ward, S. T.
Li, K. K.
Hepburn, E.
Weston, C. J.
Curbishley, S. M.
Reynolds, G. M.
Hejmadi, R. K.
Bicknell, R.
Eksteen, B.
Ismail, T.
Rot, A.
Adams, D. H.
BRITISH JOURNAL OF CANCER, 2015, 112 (02) : 319 - 328
[27] The effects of CCR5 inhibition on regulatory T-cell recruitment to colorectal cancer
S T Ward
K K Li
E Hepburn
C J Weston
S M Curbishley
G M Reynolds
R K Hejmadi
R Bicknell
B Eksteen
T Ismail
A Rot
D H Adams
British Journal of Cancer, 2015, 112 : 319 - 328
[28] Ccr5 Receptor Is A New Therapeutic Target In Pulmonary Hypertension
Amsellem, V.
Gary-Bobo, G.
Abid, S.
Poupel, L.
Houssaini, A.
Marcos, E.
Saker, M.
Mouraret, N.
Dubois-Rande, J. -L.
Combadiere, C.
Adnot, S.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
[29] CCR5 is a novel target for the treatment of experimental alopecia areata
Ito, Taisuke
Suzuki, Takahiro
Funakoshi, Atsuko
Fujiyama, Toshiharu
Tokura, Yoshiki
JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2020, 3 (02) : 24 - 32
[30] CCR5 Positive Cell Specific Targeted Transduction of a CCR5 shRNA Lentiviral Vector for HIV Gene Therapy
Anderson, Joseph S.
Nolta, Jan
Bauer, Gerhard
MOLECULAR THERAPY, 2009, 17 : S31 - S32

← 1 2 3 4 5 →